Cargando…

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment

BACKGROUND: Fostemsavir (FTR) is a prodrug of temsavir (TMR), a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells. TMR is primarily metabolized via hydrolytic and oxidative pathways; impaired hepatic function...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sevinsky, Heather, Magee, Mindy, Ackerman, Peter, Adamczyk, Robert, Karkas, Jennifer, Lubin, Susan, Ravindran, Palanikumar, Llamoso, Cyril, Eley, Timothy, Moore, Katy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630802/ http://dx.doi.org/10.1093/ofid/ofx163.1086

Ejemplares similares

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis
por: Lagishetty, Chakradhar, et al.
Publicado: (2020)

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients
por: Moore, Katy P, et al.
Publicado: (2019)

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants
por: Moore, Katy, et al.
Publicado: (2019)

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir
por: Wang, Tao, et al.
Publicado: (2021)

1315. No Dose Adjustment of Metformin with Fostemsavir Coadministration Based on Mechanistic Static and Physiologically Based Pharmacokinetic Models
por: Nguyen, Dung N, et al.
Publicado: (2020)

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
por: Anderson, Sarah-Jane, et al.
Publicado: (2021)

547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir
por: Proudfoot, Clare, et al.
Publicado: (2018)

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay
por: Gartland, Margaret, et al.
Publicado: (2020)

Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
por: Gartland, Margaret, et al.
Publicado: (2021)

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
por: Ackerman, Peter, et al.
Publicado: (2021)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

Fostemsavir for HIV-1 infection
Publicado: (2022)

Pro-Moieties of Antimicrobial Peptide Prodrugs
por: Forde, Eanna, et al.
Publicado: (2015)

Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage
por: Boutin, Marianne, et al.
Publicado: (2023)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

Xylitol as a Hydrophilization Moiety for a Biocatalytically Synthesized Ibuprofen Prodrug
por: Zappaterra, Federico, et al.
Publicado: (2022)

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies
por: Boutin, Marianne, et al.
Publicado: (2022)

Understanding the pharmacokinetics of prodrug and metabolite
por: Cho, Seungil, et al.
Publicado: (2018)

Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir
por: Prévost, Jérémie, et al.
Publicado: (2023)

Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells
por: Khoury, Aleen, et al.
Publicado: (2022)

Can changing the prodrug moiety in remdesivir be a life-saving strategy in COVID-19 infection?
por: Prabha, Praisy K., et al.
Publicado: (2023)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial
por: Chabria, Shiven, et al.
Publicado: (2021)

Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
por: Aberg, Judith A., et al.
Publicado: (2023)

A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy
por: Shan, Lingling, et al.
Publicado: (2018)

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
por: dos Santos, José Carlos, et al.
Publicado: (2022)

Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)
por: Hwang, Carey, et al.
Publicado: (2017)

Synthesis, Biological Evaluation, and Pharmacokinetic Study of Novel Liguzinediol Prodrugs
por: Liu, Zheng, et al.
Publicado: (2013)

Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
por: Bakker, Charlotte, et al.
Publicado: (2020)

Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
por: Muccini, Camilla, et al.
Publicado: (2022)

Green-adapted spectrophotometric determination of fostemsavir based on selective bromophenol blue extraction; reduction of hazardous consumption using computational calculations
por: Batubara, Afnan S., et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
por: Matsukane, Ryosuke, et al.
Publicado: (2022)

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
por: McMillan, JoEllyn, et al.
Publicado: (2017)

Enhanced Cellular Uptake and Pharmacokinetic Characteristics of Doxorubicin-Valine Amide Prodrug
por: Park, Yohan, et al.
Publicado: (2016)

Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Synthesis and antiviral activities of hexadecyloxypropyl prodrugs of acyclic nucleoside phosphonates containing guanine or hypoxanthine and a (S)-HPMP or PEE acyclic moiety
por: Tichý, Tomáš, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e5g964oln4j9m3jlnbu4ocrf2h